PUF Ventures Australia Files for Medical Research License in Collaboration with Western Sydney University

VANCOUVER, Dec. 4, 2017 /CNW/ – PUF Ventures Inc. (“PUF” or the “Company“) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce that PUF Ventures Australia (“PUFA”) has filed application with the Australian Office of Drug Control to obtain a medicinal cannabis license and a cannabis research license in collaboration with the National Institute of Complementary Medicine (NICM), an Australian Health Research Institute based at Western Sydney University in New South Wales (NSW), Australia.

PUF Ventures (CNW Group/PUF Ventures)

PUF Ventures Australia aims to conduct medical research with NICM’s academic input at its proposed Northern Rivers Project, in a 10,000-square foot dedicated laboratory, training center and research facility. When complete the facility will include an extensive 1,200,000 square feet medicinal cannabis cultivation greenhouse and extraction plant, to be located

... read more at: http://markets.businessinsider.com/news/stocks/PUF-Ventures-Australia-Files-for-Medical-Research-License-in-Collaboration-with-Western-Sydney-University-1010320811